Becton Dickinson (BDX)
Morgan Stanley analyst Drew Ranieri maintained a Buy rating on Becton Dickinson yesterday and set a price target of $310.00. The company’s shares closed last Friday at $268.85, close to its 52-week high of $272.36.
According to TipRanks.com, Ranieri is a 1-star analyst with an average return of
Becton Dickinson has an analyst consensus of Moderate Buy, with a price target consensus of $283.29, which is a 6.1% upside from current levels. In a report issued on February 3, Stifel Nicolaus also maintained a Buy rating on the stock with a $318.00 price target.
In a report released yesterday, Cecilia Furlong from Morgan Stanley maintained a Sell rating on Abiomed, with a price target of $275.00. The company’s shares closed last Friday at $295.65.
According to TipRanks.com, Furlong is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Abiomed with a $370.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BDX: